GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhibitors such as trametinib undermines clinical benefits, and the mechanisms sustaining MAPK activity under treatment remain unclear. We developed a lin-45(V627E) Caenorhabditis elegans model to mimic oncogenic BRAF signaling and found that these animals exhibited high-dose trametinib resistance, as assessed by brood size. Transcriptomic analysis revealed increased egl-30 expression in worms resistant to high-dose trametinib. Genetic and pharmacological analyses implicated EGL-30/Gαq-PLC-PKC signaling in this high-dose resistance phenotype. In trametinib-resistant A375 melanoma cells, F2RL1 , which encodes the Gαq-coupled GPCR PAR2, was upregulated compared with parental cells. Functional inhibition of PAR2 or downstream Gαq signaling reduced ERK phosphorylation and impaired the viability of trametinib-resistant melanoma cells. Furthermore, combined inhibition of MEK and Gαq-PLC-PKC signaling synergistically suppresses tumor growth and restores trametinib sensitivity in xenograft models. These findings uncover Gαq-associated signaling as a conserved contributor to trametinib resistance and a potential therapeutic vulnerability in BRAF-mutant melanoma.

Authors

Institutions

Publication Details

Journal
PLoS Genetics
Published
2026-11-19
DOI
https://doi.org/10.1371/journal.pgen.1012373
Citations
1
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

Zi Wang, Jingyi Ke, Wei Li, Guangshuo Ou et al.
1 citations
PLoS Genetics
Melanoma and MAPK Pathways
article

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

Zi Wang, Jingyi Ke, Wei Li, Guangshuo Ou, Zhengyang Guo
article en
1 citations

Abstract

Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhibitors such as trametinib undermines clinical benefits, and the mechanisms sustaining MAPK activity under treatment remain unclear. We developed a lin-45(V627E) Caenorhabditis elegans model to mimic oncogenic BRAF signaling and found that these animals exhibited high-dose trametinib resistance, as assessed by brood size. Transcriptomic analysis revealed increased egl-30 expression in worms resistant to high-dose trametinib. Genetic and pharmacological analyses implicated EGL-30/Gαq-PLC-PKC signaling in this high-dose resistance phenotype. In trametinib-resistant A375 melanoma cells, F2RL1 , which encodes the Gαq-coupled GPCR PAR2, was upregulated compared with parental cells. Functional inhibition of PAR2 or downstream Gαq signaling reduced ERK phosphorylation and impaired the viability of trametinib-resistant melanoma cells. Furthermore, combined inhibition of MEK and Gαq-PLC-PKC signaling synergistically suppresses tumor growth and restores trametinib sensitivity in xenograft models. These findings uncover Gαq-associated signaling as a conserved contributor to trametinib resistance and a potential therapeutic vulnerability in BRAF-mutant melanoma.

PLoS GeneticsVol. 22(11)
Center for Life Sciences (CN), State Key Laboratory of Membrane Biology (CN), Tsinghua University (CN)
National Natural Science Foundation of China, Tsinghua University
Good health and well-being
Melanoma and MAPK Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon